Date: 2025/05/19 - 22:32
Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly. Participants who received tirzepatide also had greater improvements in metabolic risk factors. Tirzepatide's dual effects on GLP-1 and GIP may explain its superior performance.
Date: 2025/05/08 - 17:00
Certain health conditions, such as obesity and AFib, and leading an unhealthy lifestyle can increase the functional age of the heart, causing premature aging by 5–45 years, a new study finds.
Date: 2025/03/17 - 15:01
People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label treatment, according to a new study funded by pharmaceutical company Eli Lilly.
Date: 2025/02/26 - 02:00
The CDC reported several new asymptomatic human cases of bird flu, suggesting the virus may be silently spreading and potentially a few mutations away from human-to-human transmission.
Date: 2025/01/28 - 15:31
A combination of an SGLT-2 inhibitor drug and a moderately calorie-restrictive diet leads to higher rates of type 2 diabetes remission compared to just calorie restriction alone, new research has found.